Tag Archives: Sydney

COPD update

Australian researchers have found why chronic obstructive pulmonary disease (COPD) continues long after patients have quit smoking, the primary cause of the disease.

They said cigarette smoke exposure fundamentally alters airway tissue from people with chronic obstructive pulmonary disease (COPD) at the cellular level, laying the groundwork for airway thickening and even precipitating precancerous changes in cell proliferation that may be self-perpetuating long after cigarette smoke exposure ends.

“We have demonstrated for the first time that the extracellular matrix (ECM) produced by fibroblasts following stimulation with cigarette smoke extract is functionally different than non-exposed ECM, and that the cigarette smoke itself may prime the airways in such a way to create an environment whereby airway remodelling is encouraged,” wrote lead researcher David Krimmer of the University of Sydney in Australia.

COPD

COPD

The researchers examined the response of human lung tissue from donors with and without COPD to cigarette smoke extract (CSE).

They found that CSE exposure induced a significant increase in fibronectin deposition from the tissue of donors with COPD over the tissue of individuals without COPD.

Similarly, they found that CSE upregulated the expression of perlecan—an ECM protein that is associated with tumour growth and angiogenesis—in COPD lung tissue.


Perhaps the most striking finding of the study was that the CSE-induced ECM caused fibroblasts to proliferate.

“Our findings suggest that cigarette smoking alters the composition of the lung in such a way that fibrosis becomes self-perpetuating,” explained Krimmer.

“Together these findings paint a picture of how ECM may itself perpetuate the disease process of COPD long after patients have quit smoking,” he added.

The study appeared online in the American Thoracic Society’s American Journal of Respiratory Cell and Molecular Biology.

New drug to treat heart disease and diabetes

Scientists are developing a drug which can fight both heart disease and Type 2 diabetes – and could be more effective than statins.

The drug – designed to improve levels of ‘good’ cholesterol – stabilises blood sugar levels, reducing the risk of heart disease and diabetes.

Around 2.5million Britons have Type 2 diabetes, which can be caused by excess weight and lack of exercise.

The disease increases the risks of heart disease, stroke and other heart problems.

Many sufferers use statins, a class of drugs used to lower cholesterol levels.

Now researchers at Sydney University in Australia have found that a new drug, torcetrapib, improved blood sugar control when patients took it alongside statin medicine.

They say it could give patients ‘real benefits’.

Cholesterol

Cholesterol

‘Good’ cholesterol is important as it can slow down the hardening of the arteries, lowering levels of heart problems.

Results from early trials of the drug, published in Circulation: Journal of the American Heart Association, found nearly 7,000 with Type 2 diabetes showed improved blood sugar control.

The study’s lead author, Doctor Philip Barter, a professor of medicine and director of the university’s Heart Research Institute, described the findings as ‘an exciting prospect that may translate into real health benefits for people with diabetes’.


He added that the experimental drug was not as effective in tackling diabetes as other drugs, but had the potential to prevent the disease worsening, which can occur with high doses of statins.

The clinical trial involved more than 15,000 people ages 45 to 75, who all had a history of heart attack, stroke, chest pain, peripheral vascular disease or angioplasty.

Two further drugs in the same class, dalcetrapib and anaecetrapib, are now being developed.

A spokesman for the British Heart Foundation said it was too early to say whether these further drugs would be effective.